1) Methyl ester 
Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. Phase IIb/III dose finding and evaluation trials for fragile...